Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study.

19 In the PREVAIL study, enzalutamide improved the PFS and showed a trend towards better OS compared to the placebo for chemo-naïve mCRPC patients, regardless of the presence of visceral metastases, high-volume bone metastases, and nodal only disease. 20 Taken together with our results, it is suggested that mCRPC patients presenting with adverse prognostic clinical factors could be managed similarly to those without, while clinical studies on more efficacious treatment approaches for these patients are eagerly awaited.

also in 53,322 other papers